Research programme: GPCR targeting therapeutics - Nxera Pharma/PrecisionLife
Latest Information Update: 20 Jun 2024
Price :
$50 *
At a glance
- Originator Nxera Pharma; PrecisionLife
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; CNS disorders